Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

30.48 -1.42 (-4.45%)
Streaming Delayed Price Updated: 3:25 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapport Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened ↗
Via Stocktwits
News headline image
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure... 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗
Rapport Therapeutics beats Q3 earnings estimates, reports strong Phase 2a data for its lead drug candidate RAP-219, and has cash into 2029. 
Via Chartmill
Topics Earnings
News headline image
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Rapport Announces Pricing of Public Offering of Common Stock
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Rapport Announces Proposed Public Offering of Common Stock
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Gold Moves Higher; Robinhood Shares Jump ↗
 
Via Benzinga
News headline image
Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Nasdaq Surges 150 Points; Planet Labs Shares Jump After Q2 Results ↗
 
Via Benzinga
News headline image
Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures ↗
The company is working on a treatment for a form of epilepsy that tends to be difficult to control. 
Via Investor's Business Daily
News headline image
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year ↗
Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety profile driving next steps. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Friday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.